Title | A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma |
Protocole ID | V940-001 |
ClinicalTrials.gov ID | NCT05933577 |
Cancer Type(s) | Melanoma |
Phase | Phase III |
Stage | |
Study Type | Clinical |
Drug | V940 + pembrolizumab versus placebo + pembrolizumab |
Institution |
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS 1401 18e Rue, Québec, QC, G1J 1Z4 |
City | |
Principal Investigator |
Dr. Joël Claveau |
Coordinator |
Mélanie Bradley 418-525-4444 poste 12950 |
Status | Recruiting |
Activation Date | 13-10-2023 |
Eligibility Criteria |
The main inclusion criteria include but are not limited to the following:
|
Exclusion Criteria |
The main exclusion criteria include but are not limited to the following:
|